

*South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2022 - September 30, 2023*

Department	Project Number	Project Title	Principal Investigator	Source of Funding	22-23 Receipts
Internal Medicine					
	63786	Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn's Disease (Entyvio PASS MLN-0002_401)	Dr Niland, B	Takeda Development Ctr Americas, Inc.	8,635.00
	63842	A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency (HEART-FID) (Luitpold - 1VIT15043)	Dr Malozzi, C	Luitpold Pharmaceuticals, Inc.	4,985.00
	63847	A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome (CSL112_3001)	Dr Malozzi, C	CSL Behring	8,800.00
	63891	Corrna Inflammatory Bowel Disease (IBD) Registry (IBD-600 Registry)	Dr Sonnier, W	CorEvitas	29,900.00
				Total Internal Medicine	52,320.00

**South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2022 - September 30, 2023**

Department	Project Number	Project Title	Principal Investigator	Source of Funding	22-23 Receipts
Neurology	63867	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy (Xenon XPF-008-201)	Dr Naritoku, D	Xenon Pharmaceuticals, Inc.	8,152.60
	63886	A Multicenter, Longitudinal, Open-label, Single-arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (Celgene RPC-1063-MS-001)	Dr Kilgo, W	Celgene International II Sarl	3,042.00
					Total Neurology

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2022 - September 30, 2023

Department	Project Number	Project Title	Principal Investigator	Source of Funding	22-23 Receipts
OB-GYN					
	63887	A Phase 3, Randomized, Double- or Observer-Blinded, Placebo-Controlled Trial to Evaluate The Efficacy and Safety of a Respiratory Syncytial Virus (RSV) Perfusion FSubunit Vaccine in Infants Born to Women Vaccinated During Pregnancy Investigational (Pfizer C3671008)	Dr Roth, T	Pfizer	46,868.22
				Total OB-GYN	46,868.22
Pediatrics					
	63895	A Phase II, multicenter, double blind, double dummy, randomized, 2 arms parallel study to evaluate the efficacy, safety and pharmacokinetics of CHF6563 in babies with Neonatal Opioid Withdrawal Syndrome (Chiesi CLI-06563AA1-02)	Dr Whitehurst, R	Chiesi Farmaceutici	2,050.00
	63911	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises (GBT2104-131)	Dr Marri, P	Global Blood Therapeutics, Inc.	16,626.35
	63913	An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial (GBT2104-133)	Dr Marri, P	Global Blood Therapeutics, Inc.	4,215.70
	63915	Reference Range and Clinical Performance Evaluation of Elecsys IL-6 Assay in Neonatal Sepsis (US); Collection Study (Roche Study #0165/0661)	Dr Eyal, F	Roche Diagnostics Operations, Inc.	2,631.60
	63917	A Phase 1, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan (10 or 20 mg Once Daily) in Adolescents with Symptomatic Gastroesophageal Reflux Disease (Phathom VPED-102)	Dr Gremse, D	Phathom Pharmaceuticals, Inc.	65,962.66

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2022 - September 30, 2023

Department	Project Number	Project Title	Principal Investigator	Source of Funding	22-23 Receipts
	63926	A Phase 2, Double-Blind, 12-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease (TAK-390MR_204)	Dr Gremse, D	Takeda Development Ctr Americas, Inc.	38,893.00
	63927	A Phase 2, Double-Blind, 36-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Subjects Aged 2 to 11 Years With EE (TAK-390MR_205)	Dr Gremse, D	Takeda Development Ctr Americas, Inc.	13,067.00
	63931	Evaluation of a 7-Day Therapeutic Trial Dose of Commercial Sucraid® (sacrosidase) Oral Solution for Alleviating Congenital Sucrase-Isomaltase Deficiency (CSID) Symptoms in Pediatric Subjects with Low, Moderate, and Normal Sucrase Levels (QOL - SSDXP-13)	Dr Gremse, D	QOL Medical, LLC	8,800.00
	63932	A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years (FIPCUS CLENPIQ 000359)	Dr Gremse, D	Ferring Pharmaceuticals	8,700.00
				Total Pediatrics	160,946.31

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2022 - September 30, 2023

Department	Project Number	Project Title	Principal Investigator	Source of Funding	22-23 Receipts
Surgery	63879	Use of Nexobrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries (MediWound MW2018-06-21)	Dr Bright, A	Mediowound	6,128.52
	63910	The CALIBER Study: Randomized Controlled Trial of LINX versus Double-Dose Pump Inhibitor Therapy for Reflux Disease (Torax Rethink Reflux Registry) (TRX_2018_01)	Dr Richards, W	Ethicon Endo-Surgery, Inc.	8,252.00
	63914	A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate LB1148 for Return of Gastrointestinal Function, Post-Operative Ileus and Intra-Abdominal Adhesions in Subjects Undergoing Elective Bowel Resection (PROFILE) (Palisade Bio LBS-POI-201)	Dr Rider, P	Palisade	16,099.00
	63930	A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4 Factor Prothrombin Complex Concentrate [Kcentra® / Beriplex®]) to Improve Survival in Patients with Traumatic Injury and Acute Major Bleeding (BE1116_3006)	Dr Butts, C	CSL Behring LLC	10,362.00
					Total Surgery
Mitchell Cancer Institute	63937	A Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy (LP-CT-PALO 202101)	Dr Butler, T	Xiamen LP Pharmaceuticals	9,624.00
					Total Mitchell Cancer Institute
				Total All Departments	321,794.65
Other Research Related Revenue					

*South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2022 - September 30, 2023*

Department	Project Number	Project Title	Principal Investigator	Source of Funding	22-23 Receipts
	62648	Royalty On Sales of Antibody Products	Dr Scammell, J	QED Bioscience	3,457.60
Total Other Research					3,457.60
Total					325,252.25